Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

<< Previous

Bullboard Posts

Next >>

Post by palinc2000on Apr 15, 2021 10:25am

93 Views

Post# 32999962

Among Goals for the current year

Seek and pursue potential product acquisitions, in-licensing transactions or other opportunities complementary to our business; and, Manage our financial position to ensure we can successfully execute on our business strategy and objectives

I wonder if they are really pursuing and seeking acquisitions and licensing or similar,,,,,Is this just boiler plate just in case or is there more ?

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market